Published in J Clin Microbiol on July 01, 2000
Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev (2005) 5.69
The role of toxin A and toxin B in Clostridium difficile infection. Nature (2010) 5.32
Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol (2002) 3.30
Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol (2004) 2.82
Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol (2001) 2.42
Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol (2003) 2.24
Multilocus sequence typing analysis of human and animal Clostridium difficile isolates of various toxigenic types. J Clin Microbiol (2004) 2.11
Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol (2004) 2.09
Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol (2006) 1.87
Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J Clin Microbiol (2003) 1.87
Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Microbiol (2002) 1.83
Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol (2004) 1.73
New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol (2003) 1.61
Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol (2008) 1.47
Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol (2003) 1.43
Application of isothermal helicase-dependent amplification with a disposable detection device in a simple sensitive stool test for toxigenic Clostridium difficile. J Mol Diagn (2008) 1.41
Algorithm combining toxin immunoassay and stool culture for diagnosis of Clostridium difficile infection. J Clin Microbiol (2009) 1.34
Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol (2009) 1.33
Analysis of Clostridium difficile isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan. J Clin Microbiol (2001) 1.26
Microarray identification of Clostridium difficile core components and divergent regions associated with host origin. J Bacteriol (2009) 1.24
International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J Clin Microbiol (2003) 1.23
High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis (2003) 1.20
Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. BMC Infect Dis (2009) 1.10
Rapid and simple method for detecting the toxin B gene of Clostridium difficile in stool specimens by loop-mediated isothermal amplification. J Clin Microbiol (2005) 1.07
Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes (2011) 1.06
Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLoS One (2013) 1.04
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine (2008) 1.03
Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Sci Rep (2014) 1.00
Evaluation of two rapid immunochromatography tests for the detection of Clostridium difficile toxins. Dig Dis Sci (2007) 0.99
The host immune response to Clostridium difficile infection. Ther Adv Infect Dis (2013) 0.96
Diversity and Evolution in the Genome of Clostridium difficile. Clin Microbiol Rev (2015) 0.94
Emergence of Clostridium difficile NAP1 in Latin America. J Clin Microbiol (2009) 0.93
Recent emergence of an epidemic clindamycin-resistant clone of Clostridium difficile among Polish patients with C. difficile-associated diarrhea. J Clin Microbiol (2003) 0.90
Clostridium difficile-associated colitis. Can Fam Physician (2004) 0.88
Clonal spread of a Clostridium difficile strain with a complete set of toxin A, toxin B, and binary toxin genes among Polish patients with Clostridium difficile-associated diarrhea. J Clin Microbiol (2005) 0.87
Sensitive quantification of Clostridium difficile cells by reverse transcription-quantitative PCR targeting rRNA molecules. Appl Environ Microbiol (2012) 0.87
Essential role of toxin A in C. difficile 027 and reference strain supernatant-mediated disruption of Caco-2 intestinal epithelial barrier function. Clin Exp Immunol (2008) 0.84
Clinical and microbiologic characteristics of tcdA-negative variant Clostridium difficile infections. BMC Infect Dis (2012) 0.84
Genotypic investigation of Clostridium difficile in Prince Edward Island. Can J Infect Dis Med Microbiol (2008) 0.82
The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins. Toxins (Basel) (2015) 0.77
Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks. Emerg Microbes Infect (2016) 0.76
Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One Region. Can J Infect Dis Med Microbiol (2016) 0.76
Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. Ann Lab Med (2015) 0.75
Comparative genome analysis and global phylogeny of the toxin variant Clostridium difficile PCR Ribotype 017 reveals the evolution of two independent sub-lineages. J Clin Microbiol (2016) 0.75
Clostridium difficile: an emerging pathogen in children. Discov Med (2012) 0.75
Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model. Front Microbiol (2017) 0.75
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol (1998) 4.79
Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol (1995) 4.39
Clostridium difficile--associated diarrhea. Clin Infect Dis (1998) 4.06
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Application of typing by pulsed-field gel electrophoresis to the study of Clostridium difficile in a neonatal intensive care unit. J Clin Microbiol (1994) 3.51
Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis (1992) 3.37
Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol (1998) 3.34
Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest (1988) 3.12
Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol (1996) 2.85
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Clostridium difficile: clinical considerations. Rev Infect Dis (1990) 2.28
Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.07
An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep (1999) 2.04
Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet (1992) 2.00
Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches. J Clin Microbiol (1998) 1.89
Characterization of polymorphisms in the toxin A and B genes of Clostridium difficile. FEMS Microbiol Lett (1997) 1.88
Closing in on the toxic domain through analysis of a variant Clostridium difficile cytotoxin B. Mol Microbiol (1995) 1.81
Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. J Med Microbiol (1993) 1.78
Clostridial disease of the gut. Clin Infect Dis (1995) 1.64
Purification and characterisation of toxin B from a strain of Clostridium difficile that does not produce toxin A. J Med Microbiol (1991) 1.63
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology (1992) 1.62
Clostridium difficile toxin A and its effects on cells. Toxicon (1991) 1.54
Identification and characterization of adhesive factors of Clostridium difficile involved in adhesion to human colonic enterocyte-like Caco-2 and mucus-secreting HT29 cells in culture. Mol Microbiol (1993) 1.22
Nontoxigenic strains of Clostridium difficile lack the genes for both toxin A and toxin B. J Clin Microbiol (1991) 1.20
Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease. Emerg Infect Dis (1999) 1.16
Identification of toxigenic Clostridium difficile strains by using a toxin A gene-specific probe. J Clin Microbiol (1990) 1.04
Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol (1997) 1.03
Biological mode of action of Clostridium difficile toxin A: a novel enterotoxin. J Med Microbiol (1987) 0.98
Clostridium difficile: a pathogen of the nineties. Eur J Clin Microbiol Infect Dis (1998) 0.91
Surgical aspects of Clostridium difficile colitis. Br J Surg (1997) 0.89
Demonstration of toxin A and B by polymerase chain reaction and McCoy cell assay in clinical isolates of Clostridium difficile from Denmark. APMIS (1993) 0.85
Separate isolation of Clostridium difficile spores and vegetative cells from the feces of newborn infants. Microbiol Immunol (1992) 0.81
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med (1987) 8.41
Necessity of quality-controlled 16S rRNA gene sequence databases: identifying nontuberculous Mycobacterium species. J Clin Microbiol (2001) 4.63
Rapid geographic spread of a methicillin-resistant Staphylococcus aureus strain. Clin Infect Dis (1997) 2.65
Diagnosis of pathogenic Entamoeba histolytica infection using a stool ELISA based on monoclonal antibodies to the galactose-specific adhesin. J Infect Dis (1993) 2.57
In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother (1997) 2.51
Rapid diagnosis of Entamoeba infection by using Entamoeba and Entamoeba histolytica stool antigen detection kits. J Clin Microbiol (1995) 2.31
Bacteriuria in elderly institutionalized men. N Engl J Med (1983) 2.20
Clinical significance of a test for slime production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci. J Infect Dis (1987) 2.10
Multicenter evaluation of the Clostridium difficile TOX A/B TEST. J Clin Microbiol (1998) 2.09
The association of urinary tract infection with sexual intercourse. J Infect Dis (1982) 2.05
An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital. Can Commun Dis Rep (1999) 2.04
The postantibiotic effect: a review of in vitro and in vivo data. DICP (1991) 1.91
A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother (2000) 1.89
Characterization of coagulase-negative staphylococci from urinary tract specimens. J Clin Microbiol (1983) 1.81
Diagnosis of amebic liver abscess and intestinal infection with the TechLab Entamoeba histolytica II antigen detection and antibody tests. J Clin Microbiol (2000) 1.77
A controlled study of antimicrobial prophylaxis of recurrent urinary infection in women. N Engl J Med (1974) 1.74
Influence of mucoidy on antibody coating of Pseudomonas aeruginosa. J Infect Dis (1979) 1.67
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med (1979) 1.64
Survey of anaerobic susceptibility patterns in Canada. Antimicrob Agents Chemother (1986) 1.60
Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun (2000) 1.60
Intraabdominal infection: a review. Clin Infect Dis (1994) 1.54
Febrile urinary infection in the institutionalized elderly. Am J Med (1996) 1.47
Estimating the impact of amebiasis on health. Parasitol Today (2000) 1.43
Urinary antibody level and survival in bacteriuric institutionalized older subjects. J Am Geriatr Soc (1998) 1.40
Selective bowel decontamination does not alter hepatic regeneration in rats. Gastroenterology (1992) 1.39
Single dose medication vial packaging deficiencies. Can J Anaesth (1998) 1.39
Review of macrolides and ketolides: focus on respiratory tract infections. Drugs (2001) 1.39
Purification and characterization of a Serratia marcescens metalloprotease. Infect Immun (1979) 1.39
Photo quiz. Symmetric peripheral gangrene. Clin Infect Dis (1996) 1.37
Biotyping of Escherichia coli by a simple multiple-inoculation agar plate technique. J Clin Microbiol (1979) 1.36
Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J Infect Dis (1986) 1.34
Substance P activation of enteric neurons in response to intraluminal Clostridium difficile toxin A in the rat ileum. Gastroenterology (1996) 1.32
Mycobacterium parascrofulaceum sp. nov., novel slowly growing, scotochromogenic clinical isolates related to Mycobacterium simiae. Int J Syst Evol Microbiol (2004) 1.32
Urinary tract infection localization in women. JAMA (1978) 1.30
Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol (2000) 1.28
Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev (2008) 1.28
Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba Diabetic Urinary Infection Study Group. Clin Infect Dis (1995) 1.27
The association of bacteriuria with resident characteristics and survival in elderly institutionalized men. Ann Intern Med (1987) 1.24
Group C streptococcal meningitis in an adult. Probable acquistion from a horse. Arch Intern Med (1980) 1.23
Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother (1986) 1.23
Hospitalization for acute pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of diabetes, pregnancy, and aboriginal origin. Clin Infect Dis (1996) 1.23
Characterization of rabbit corneal damage produced by Serratia keratitis and by a serratia protease. Infect Immun (1981) 1.23
Expert opinion on the management of infections in the diabetic foot. Diabetes Metab Res Rev (2012) 1.22
Characterization of bacteroides melaninogenicus. J Clin Microbiol (1976) 1.21
Therapy for acute cystitis in adult women. Randomized comparison of single-dose sulfisoxazole vs trimethoprim-sulfamethoxazole. JAMA (1982) 1.21
Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med (1995) 1.17
Helicobacter pylori in the Canadian arctic: seroprevalence and detection in community water samples. Am J Gastroenterol (1999) 1.16
Preservation of colonization resistance parameters during empiric therapy with aztreonam in the febrile neutropenic patient. Rev Infect Dis (1986) 1.14
Prophylaxis of recurrent urinary tract infection in female patients. Efficacy of low-dose, thrice-weekly therapy with trimethoprim-sulfamethoxazole. JAMA (1979) 1.13
Short report: detection of Entamoeba histolytica and E. dispar directly in stool. Am J Trop Med Hyg (1994) 1.10
Seroprevalence of Helicobacter pylori, incidence of gastric cancer, and peptic ulcer-associated hospitalizations in a Canadian Indian population. Dig Dis Sci (1999) 1.10
Prospective, randomized comparative study of clindamycin, chloramphenicol, and ticarcillin, each in combination with gentamicin, in therapy for intraabdominal and female genital tract sepsis. J Infect Dis (1980) 1.09
Prospective study of decubitus ulcers in two long term care facilities. Can J Infect Control (1994) 1.08
Anaerobic and aerobic urethral flora in healthy females. J Clin Microbiol (1978) 1.07
Serological study of responses to selected pathogens causing respiratory tract infection in the institutionalized elderly. Clin Infect Dis (1996) 1.07
Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains. Antimicrob Agents Chemother (1983) 1.06
Mycobacterium saskatchewanense sp. nov., a novel slowly growing scotochromogenic species from human clinical isolates related to Mycobacterium interjectum and Accuprobe-positive for Mycobacterium avium complex. Int J Syst Evol Microbiol (2004) 1.05
Prospective, randomized, comparative trials in the therapy for intraabdominal and female genital tract infections. Rev Infect Dis (1984) 1.04
Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis. Infection (1982) 1.04
In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species. Antimicrob Agents Chemother (1997) 1.04
Complicated urinary tract infections. Infect Dis Clin North Am (1997) 1.02
Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora. Antimicrob Agents Chemother (1984) 1.02
Localization of urinary tract infection in elderly, institutionalized women with asymptomatic bacteriuria. J Infect Dis (1988) 1.02
Pseudomonas cepacia colonization and infection in intensive care units. CMAJ (1986) 1.01
Nocardia asteroides cerebral abscess in immunocompetent hosts: report of three cases and review of surgical recommendations. Surg Neurol (2000) 1.00
Susceptibility of clinical isolates of Staphylococcus saprophyticus to fifteen commonly used antimicrobial agents. Antimicrob Agents Chemother (1982) 1.00
Prospective assessment of risk of bacteremia with colonoscopy and polypectomy. Dig Dis Sci (1987) 0.99
Salmonella urinary tract infections associated with exposure to pet iguanas. Clin Infect Dis (1997) 0.98
M. tuberculosis molecular variation in CNS infection: evidence for strain-dependent neurovirulence. Neurology (1998) 0.98
Prospective, randomized, placebo-controlled trial of norfloxacin for the prophylaxis of recurrent urinary tract infection in women. Antimicrob Agents Chemother (1989) 0.98
Granulocytopenia in hospitalized patients. II. A prospective comparison of two antibiotic regimens in the empiric therapy of febrile patients. Am J Med (1978) 0.97
Clostridial toxins active locally in the gastrointestinal tract. Ciba Found Symp (1985) 0.97
Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother (1994) 0.96
Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile. J Hosp Infect (2009) 0.96
Clinical experiences: genitourinary infections. A. Infections of the urinary tract. Efficacy of trimethoprim-sulfamethoxazole in bacteriuria. J Infect Dis (1973) 0.95
Production and characterization of chimeric transferrins for the determination of the binding domains for bacterial transferrin receptors. J Biol Chem (1996) 0.94
Inactivation of human plasma alpha 1-proteinase inhibitor by a metalloproteinase from Serratia marcescens. Biochim Biophys Acta (1982) 0.94
Advances in the treatment of urinary tract infection. Am J Med (1984) 0.94
Prospective randomized comparison of imipenem/cilastatin and cefotaxime for treatment of lung, soft tissue, and renal infections. Rev Infect Dis (1985) 0.94
Emergence of rifampin-resistant Haemophilus influenzae. Antimicrob Agents Chemother (1982) 0.94
Calcific myonecrosis: case report and review. Ann Plast Surg (2001) 0.94
Granulocytopenia in hospitalized patients: I. Prognostic factors and etiology of fever. Am J Med (1978) 0.93
Infectious complications of endoscopic injection sclerotherapy. Arch Intern Med (1986) 0.93
Isolation of toxigenic Clostridium difficile from dialysate fluid in a fatal case of chronic ambulatory peritoneal dialysis-related peritonitis. Clin Infect Dis (1997) 0.92
Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women. Rev Infect Dis (1982) 0.92
Clinical efficacy and toxicity of netilmicin in the treatment of gram-negative infections. Can Med Assoc J (1979) 0.91
A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia. J Antimicrob Chemother (1987) 0.91
Fecal carriage of various Klebsiella and Enterobacter species in patients with active ankylosing spondylitis. Arthritis Rheum (1981) 0.91
Amoxicillin therapy of acute urinary infections in adults. Antimicrob Agents Chemother (1977) 0.91
A prospective, randomized, double-blind studyof single high dose versus multiple standard dose gentamicin both in combination withmetronidazole for colorectal surgicalprophylaxis. J Hosp Infect (2000) 0.90
Improved detection of bacterial growth in continuous ambulatory peritoneal dialysis effluent by use of BacT/Alert FAN bottles. J Clin Microbiol (1997) 0.90
Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis (1988) 0.90
A comparison of the efficacy of nalidixic acid and cephalexin in bacteriuric women and their effect on fecal and periurethral carriage of enterobacteriaceae. J Infect Dis (1981) 0.90
Specific guidelines for the treatment of diabetic foot infections 2011. Diabetes Metab Res Rev (2012) 0.89
A Salmonella Typhimurium 197 outbreak linked to the consumption of lambs' liver in Sydney, NSW. Epidemiol Infect (2007) 0.89